ea0099p260 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024
Rebrova Yanina
, Saienko Yana
, Mankovsky Borys
, Marushko Ievgen
Background: Chronic kidney disease develops in approximately 40% of patients with type 2 diabetes mellitus (T2DM) and significantly increases the risk of mortality and cardiovascular morbidity. Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, has demonstrated a significant impact on renal function by reducing proteinuria and preserving glomerular filtration rate in patients with chronic kidney disease. However, the influence of finerenone on kidney funct...